Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6490)
All Articles published online
|
Publishing Process of This Article
|
Dec 21, 2021 (publication date) through Nov 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021; 27(47): 8069-8080 [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v27/i47/8069.htm |
| Number | Citing Articles |
| 1 |
Qiao Ke, Fuli Xin, Huipeng Fang, Yongyi Zeng, Lei Wang, Jingfeng Liu. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.913464
|
| 2 |
Qianyi Lin, Dexiong Chen, Kangde Li, Xiaomin Fan, Qi Cai, Weihong Lin, Chunhong Qin, Tao He. Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality Therapy. Frontiers in Radiology 2022; 2 doi: 10.3389/fradi.2022.858963
|
| 3 |
Xuefeng Gu, Yanyan Wei, Duo Shen, Yuan Mao. Construction of a prognostic model for disulfidptosis-related long noncoding RNAs in R0 resected hepatocellular carcinoma and analysis of their impact on malignant behavior. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12816-3
|
| 4 |
Jing-Nan Xue, Yan-Yu Wang, Yun-Chao Wang, Nan Zhang, Long-Hao Zhang, Zheng-Hui Lu, Li-Jin Zhao, Hai-Tao Zhao. Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary & Pancreatic Diseases International 2022; 21(5): 450 doi: 10.1016/j.hbpd.2022.08.014
|
| 5 |
Bowen Chen, Jin Lei, Haitao Zhao, Jinghui Dong, Zhen Zeng, Yinyin Li, Lingxiang Yu, Lin Zhou, Aiying Jia, Yinying Lu, Jiamin Cheng. Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. Journal of Hepatocellular Carcinoma 2022; : 1171 doi: 10.2147/JHC.S387254
|
| 6 |
Xinlin Li, Kai Chen, Xu Feng, Xinhua Wu, Shiguai Qi, Qingmiao Wang, Zhengrong Shi. A Comparative Study of Surgical Approaches for Hepatocellular Carcinoma: Conversion versus Direct Resection. Journal of Hepatocellular Carcinoma 2024; : 2101 doi: 10.2147/JHC.S483397
|
| 7 |
Yong-Guang Wei, Hao Su, Zi-li Lv, Xi-Wen Liao, Zhi-Ming Zeng, Yu-Xuan Jia, Hua-Sheng Huang, Xiao-Qiang Shen, Guang-Zhi Zhu, Chuang-Ye Han, Xin-Ping Ye, Tao Peng. Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1165538
|
| 8 |
Renguo Guan, Chengyou Yu, Shaohua Li, Jie Mei, Wei Wei, Rongping Guo. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.998534
|
| 9 |
Kang Chen, Cheng-Piao Luo, De-Xiang Ge, Ke-Lin Wang, Qin Luo, Yan-Zhi Li, Xue-Mei You, Bang-De Xiang, Le-Qun Li, Liang Ma, Jian-Hong Zhong. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.946693
|
| 10 |
Qingwei Zhu, Wei Rao, Junyu Huo, Zixiang Li, Song Wang, Wensheng Qiu, Ge Guan, Yang Xin, Ning Fan, Jinzhen Cai, Liqun Wu. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02661-2
|
| 11 |
Jia-Lin Wu, Jun-Yang Luo, Zai-Bo Jiang, Si-Bo Huang, Ge-Run Chen, Hui-Ying Ran, Qi-Yue Liang, Ming-Sheng Huang, Li-Sha Lai, Jun-Wei Chen. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy. World Journal of Gastroenterology 2023; 29(20): 3168-3184 doi: 10.3748/wjg.v29.i20.3168
Abstract(492) |
Core Tip(494) |
Full Article(HTML)(1865)
|
Full Article (PDF)-3361K(88)
|
Full Article (Word)-1704K(22)
|
Audio-11856K(8)
|
Peer-Review Report-309K(47)
|
Answering Reviewers-162K(49)
|
Supplementary Material-712K(48)
|
Full Article (PDF)-3169K(110)
|
Times Cited (1)
|
Total Visits (6552)
|
Open
|
| 12 |
Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular carcinoma. Cancer Medicine 2024; 13(9) doi: 10.1002/cam4.7105
|
| 13 |
Wenxuan Li, Zhikai Zheng, Jiongliang Wang, Tianqing Wu, Juncheng Wang, Yangxun Pan, Jinbin Chen, Dandan Hu, Li Xu, Yaojun Zhang, Minshan Chen, Zhongguo Zhou. Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy. Journal of Hepatocellular Carcinoma 2024; : 463 doi: 10.2147/JHC.S447387
|
| 14 |
Ming‐Da Wang, Xue‐Jun Xu, Ke‐Chun Wang, Yong‐Kang Diao, Jia‐Hao Xu, Li‐Hui Gu, Lan‐Qing Yao, Chao Li, Guo‐Yue Lv, Tian Yang. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Cancer Science 2024; 115(7): 2159 doi: 10.1111/cas.16194
|
| 15 |
Zheyu Zhou, Xiaoliang Xu, Meiling Sun, Yang Liu, Qiaoyu Liu, Chaobo Chen, Yin Yin. Conversion therapy for massive hepatocellular carcinoma: A case report and literature review. Clinical Case Reports 2023; 11(6) doi: 10.1002/ccr3.7533
|
| 16 |
Tatsuya Orimo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas. Annals of Surgical Oncology 2022; 29(13): 8436 doi: 10.1245/s10434-022-12495-z
|
| 17 |
Haoyang Bei, Weiheng Mai, Weifeng Chen, Mingyi Li, Yongguang Yang. Application of systemic treatment in conversion therapy options for liver cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.966821
|
| 18 |
Yueping Liu, Meiling Sun. An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients. Clinics and Research in Hepatology and Gastroenterology 2023; 47(8): 102195 doi: 10.1016/j.clinre.2023.102195
|
| 19 |
Zheyu Zhou, Chaobo Chen, Meiling Sun, Xiaoliang Xu, Yang Liu, Qiaoyu Liu, Jincheng Wang, Yin Yin, Beicheng Sun. A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study. PeerJ 2023; 11: e15950 doi: 10.7717/peerj.15950
|
| 20 |
Haowen Tang, Yinbiao Cao, Yiping Jian, Xuerui Li, Junfeng Li, Wenwen Zhang, Tao Wan, Zhe Liu, Wei Tang, Shichun Lu. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. BioScience Trends 2022; 16(2): 130 doi: 10.5582/bst.2022.01019
|
| 21 |
Jia-Yi Wu, Jun-Yi Wu, De-Yi Liu, Han Li, Shao-Wu Zhuang, Bin Li, Jian-Yin Zhou, Jing-Yao Huang, Zhi-Bo Zhang, Shu-Qun Li, Mao-Lin Yan, Yao-Dong Wang. Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?. Journal of Hepatocellular Carcinoma 2023; : 2161 doi: 10.2147/JHC.S442341
|
| 22 |
Ren Ziwang, Feng Guiling, Feng Xu, Liu Zhu, Li Bing, Du Yong. Comparative Study of CT and MR Guided Microwave Ablation in the
Treatment of Para-vascular VX2 Liver Tumor Model in Rabbits. Current Medical Imaging Reviews 2023; 20 doi: 10.2174/1573405620666230908111713
|
| 23 |
Yining Wu, Shenjian Ou, Xiwen Liao, Chuangye Han, Chengkun Yang, Wei Qin, Yufeng Tan, Quan Lao, Tao Peng, Xinping Ye. Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report. Pharmacogenomics and Personalized Medicine 2023; : 111 doi: 10.2147/PGPM.S376596
|
| 24 |
Suqi Zhu, Yahan Yu, Mingqi Yang, Xin Liu, Mingkai Lai, Jieren Zhong, Xiaoguang Zhao, Ligong Lu, Yanyan Liu. Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review. Expert Review of Anticancer Therapy 2024; 24(6): 423 doi: 10.1080/14737140.2024.2346624
|